Education
About Us
Working with TipRanks
Follow Us
Solventum Corporation (SOLV)
NYSE:SOLV
SOLV Stock Chart & Stats
$85.59
-$0.47(-0.68%)
At close: 4:00 PM EST
$85.59
-$0.47(-0.68%)
Day’s Range― - ―
52-Week Range$60.70 - $88.20
Previous CloseN/A
Volume531.14K
Average Volume (3M)1.04M
Market Cap
$14.85B
Enterprise Value$16.30B
Total Cash (Recent Filing)$1.64B
Total Debt (Recent Filing)$5.14B
Price to Earnings (P/E)9.9
Beta0.58
Next Earnings
Feb 26, 2026EPS Estimate
1.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.50
Shares Outstanding173,447,560
10 Day Avg. Volume1,098,524
30 Day Avg. Volume1,042,814
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)3.87
Price to Sales (P/S)1.39
P/FCF Ratio14.21
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue1.94
Enterprise Value/Gross Profit3.55
Enterprise Value/Ebitda6.29
Forecast
1Y Price Target
$89.38Price Target Upside4.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)6.02
Revenue Forecast (FY)$8.25B
Bulls Say, Bears Say
Bulls Say
Acquisition And Share RepurchaseSOLV announced a definitive agreement to acquire Acera Surgical for ~$725M cash and up to $125M in contingent cash payments based on the achievement of certain future milestones, along with a ~$1B share repurchase program expected to begin in FY26.
Cost Savings And Margin ImprovementSOLV's 'Transform for the Future' initiative aims to improve its cost structure and generate $500M in annual cost savings, positioning it to improve its margin structure and drive operational margin expansion.
Growth In Regenerative Wound CareAcera's technology will enable Solventum to better compete in the faster-growing regenerative wound care space, aligning with SOLV's surgical exposure and focus on hard-to-heal wounds.
Bears Say
EPS Dilution And Tariff ImpactsThe deal is expected to be slightly dilutive to adjusted EPS in FY26, with SOLV likely to see more muted EPS growth due to the tariff impacts and limited OMX.
Growth Environment ChallengesThere is a conservative posture for the remainder of the year and into 2026 as the company navigates a growth environment challenged by SKU rationalization and tougher comps.
Integration RisksIntegration will be a key risk given SOLV is still early in its lifecycle as a public company and it is relatively entangled with 3M.
Solventum Corporation News
SOLV FAQ
What was Solventum Corporation’s price range in the past 12 months?
Solventum Corporation lowest stock price was $60.70 and its highest was $88.20 in the past 12 months.
What is Solventum Corporation’s market cap?
Solventum Corporation’s market cap is $14.85B.
When is Solventum Corporation’s upcoming earnings report date?
Solventum Corporation’s upcoming earnings report date is Feb 26, 2026 which is in 84 days.
How were Solventum Corporation’s earnings last quarter?
Solventum Corporation released its earnings results on Nov 06, 2025. The company reported $1.5 earnings per share for the quarter, beating the consensus estimate of $1.43 by $0.07.
Is Solventum Corporation overvalued?
According to Wall Street analysts Solventum Corporation’s price is currently Undervalued.
Does Solventum Corporation pay dividends?
Solventum Corporation does not currently pay dividends.
What is Solventum Corporation’s EPS estimate?
Solventum Corporation’s EPS estimate is 1.49.
How many shares outstanding does Solventum Corporation have?
Solventum Corporation has 173,447,560 shares outstanding.
What happened to Solventum Corporation’s price movement after its last earnings report?
Solventum Corporation reported an EPS of $1.5 in its last earnings report, beating expectations of $1.43. Following the earnings report the stock price went up 7.906%.
Which hedge fund is a major shareholder of Solventum Corporation?
Currently, no hedge funds are holding shares in SOLV
Solventum Corporation Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$89.38 (4.43% Upside)
$89.38 (4.43% Upside)
Blogger Sentiment
Bullish
SOLV Sentiment 66%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.64%
12-Months-Change
Fundamentals
Return on Equity
37.25%
Trailing 12-Months
Asset Growth
-5.24%
Trailing 12-Months
Company Description
Solventum Corporation
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
SOLV Company Deck
SOLV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Solventum reported strong sales growth, successful portfolio optimization, and a transformed balance sheet, positioning the company for future growth and acquisitions. However, tariff headwinds and segment-specific challenges pose risks. Overall, the highlights significantly outweigh the lowlights, reflecting a positive outlook.View all SOLV earnings summariesSOLV Stock 12 Month Forecast
Average Price Target
$89.38
▲(4.43% Upside)
Technical Analysis
DaVita
―
Fresenius Medical Care
―
Encompass Health
―
Tenet Healthcare
―
Universal Health
―
Ownership Overview
14.87% Insiders
18.10% Mutual Funds
27.56% Other Institutional Investors
18.88% Public Companies and
Individual Investors